• Home
  • Photo News
  • News
    • NGO/CSO
    • Photo News
    • OrientalNews 7th Anniversary
    • Press Releases
    • World News
    • Nigeria News
    • Politics
    • Opinion
    • Sports
  • Interviews
  • SMEs
  • Law
    • Crime
  • Travel & Tours
    • Aviation
    • Tourism
  • Energy
    • Oil & Gas
    • Power
  • Business
    • Banking & Finance
      • Capital Market
      • Money Market
    • Pension
    • Insurance
    • Brands & Marketing
    • IT & Telecoms
    • Labour
    • Agriculture
    • Maritime
    • Property
    • Manufacturing
  • Regulators
    • Nigeria Bureu of Statistics
    • PENCOM
    • NAICOM
    • SEC
    • NSE
    • CBN
Facebook X (Twitter) Instagram
Thursday, March 12
  • About us
  • Terms of use
  • Privacy Policy
  • Disclaimer
  • Advertize here
  • Contact us
Facebook X (Twitter) Instagram
Oriental News Nigeria
  • Home
  • Photo News
  • News
    • NGO/CSO
    • Photo News
    • OrientalNews 7th Anniversary
    • Press Releases
    • World News
    • Nigeria News
    • Politics
    • Opinion
    • Sports
  • Interviews
  • SMEs
  • Law
    • Crime
  • Travel & Tours
    • Aviation
    • Tourism
  • Energy
    • Oil & Gas
    • Power
  • Business
    • Banking & Finance
      • Capital Market
      • Money Market
    • Pension
    • Insurance
    • Brands & Marketing
    • IT & Telecoms
    • Labour
    • Agriculture
    • Maritime
    • Property
    • Manufacturing
  • Regulators
    • Nigeria Bureu of Statistics
    • PENCOM
    • NAICOM
    • SEC
    • NSE
    • CBN
Oriental News Nigeria
Home»News»Nigeria News»NAFDAC Warns Of Fast Circulating Fake Anti-Hypertensive Drugs In The Market
Nigeria News

NAFDAC Warns Of Fast Circulating Fake Anti-Hypertensive Drugs In The Market

By Orientalnews StaffApril 24, 2019No Comments3 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

Yemisi Izuora 

The National Agency for Food, Drug Administration and Control (NAFDAC) has issued a warning alerting the public that a fake anti-hypertensive drug is in circulation.

Prof Moji Adeyeye, NAFDAC’s Director General (DG) in a statement on Tuesday in Abuja, said the drug, Hydrochlorothiazide 50mg (containing Glibenclamide) was currently circulating in Cameroun.

“NAFDAC is alerting the public, especially healthcare providers on the circulation of confirmed falsified Hydrochlorothiazide 50mg tablets in Cameroun. The falsified product has been found to contain Glibenclamide instead of Hydrochlorothiazide. In March 2019, the World Health Organisation (WHO) was informed by an NGO in Cameroun that a medicine, presented as Hydrochlorothiazide 50mg tablets, has caused hypoglycaemia in patients. Confirmatory laboratory analysis has established that the product did not contain hydrochlorothiazide, the stated active ingredient, glibenclamide was instead identified,” Adeyeye said.

She explained that the genuine version of the drug was for treatment of hypertension.

According to her, the falsified medicine poses grave danger to patients.

“Hydrochlorothiazide is used as an anti-hypertensive and diuretic medicine, whereas Glibenclamide is an anti-diabetic medicine. The falsified medicine presents a risk for patients who are taking hydrochlorothiazide for the treatment of hypertension. The label on the plastic container of this falsified product states Laboratoires Sterop as the manufacturer, however, this company has confirmed to WHO that it did not manufacture or supply the falsified product. The Falsified hydrochlorothiazide 50mg is presented in plastic containers of 1000 tablets each,” she said.

The NAFDAC DG further said the drug which had a batch number of 16G04, also carried 16/2017 as its Manufacture Date and 30/05/2021 as Expiry Date.

“The batch number, as well as a number of other features shown on the label of the falsified Hydrochlorothiazide 50mg tablets, do not correspond with genuine manufacturing records. The label is English and French languages.

She advised importers, wholesalers, and retailers to avoid illegal importation and sale of the drug in Nigeria as surveillance had been heightened to prevent such.

“Surveillance has been strengthened by NAFDAC at all ports of entry to prevent importation of the falsified Hydrochlorothiazide 50mg tablets from Cameroun. NAFDAC has also heightened surveillance to prevent distribution and sale of the falsified product. Healthcare providers and other members of the public are advised to be vigilant and contact the nearest NAFDAC office with any information on the product,” she said.

Adeyeye further advised those already in possession of the drug to submit it to the nearest NAFDAC office.

She advised consumers to report any adverse effects related to the use of medicines to the nearest NAFDAC office, its Toll Free number 20543, to all Networks, or via its e-mail pharmacovigilance@nafdac.gov.ng

Share this:

  • Share
  • Click to email a link to a friend (Opens in new window) Email
  • Tweet
  • Click to share on Reddit (Opens in new window) Reddit
cover
Orientalnews Staff

Related Posts

Godman Akinlabi Earns Transformational Leadership Award at Nigerian Legal Awards

March 2, 2026

Tinubu Charges New Police Chief To Improve Security Across The Country 

February 26, 2026

Joyce Ojemudia Foundation Launch To Address Neonatal Mortality, Infertility Challenges 

February 23, 2026

Leave A Reply Cancel Reply

The latest
  • NIMASA DG Pushes Digital Shift To Boost Women’s Role In Maritime Sector
  • NGX Group, IFC Others Convene Leaders To Advance Gender Equality At 2026 Ring The Bell Ceremony
  • Union Bank Of Nigeria Marks International Women’s Month 2026 With Inclusion-First “Give to Gain” Campaign
  • Make Integrity Your Foundation,  Olukoyede Charges Students
  • SEC Unveils Platform To Bridge Regulatory Gaps In Nigeria’s FinTech Sector
  • Lagos State Promises Enhanced Service Delivery, Set To Unveil New Facilities 
  • Bristow Group Receives 2 Airbus H160 Helicopters To Boost Nigeria’s Aviation Operations 
  • INEC Restates Commitment To Gender Inclusion 
  • NYSC Promotes Technology Adoption By LGIs To Achieve Service Delivery 
  • IWD: Fidelity Bank Signs MoU With  Partners, Launch ‘Give Her Power’ Initiative To Empower Nigerian Women
Categories
Quick Links
  • About us
  • Terms of use
  • Privacy Policy
  • Disclaimer
  • Advertize here
  • Contact us
Facebook X (Twitter) Instagram YouTube LinkedIn
Copyright © 2026 Oriental News Nigeria. All right reserved.

Type above and press Enter to search. Press Esc to cancel.